A detailed history of Oppenheimer Asset Management Inc. transactions in Genmab A/S stock. As of the latest transaction made, Oppenheimer Asset Management Inc. holds 232,243 shares of GMAB stock, worth $4.78 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
232,243
Previous 218,078 6.5%
Holding current value
$4.78 Million
Previous $5.48 Million 3.32%
% of portfolio
0.07%
Previous 0.07%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$23.84 - $28.48 $337,693 - $403,419
14,165 Added 6.5%
232,243 $5.66 Million
Q2 2024

Aug 08, 2024

BUY
$25.13 - $30.27 $1.14 Million - $1.37 Million
45,376 Added 26.27%
218,078 $5.48 Million
Q1 2024

May 06, 2024

SELL
$26.43 - $32.77 $289,434 - $358,864
-10,951 Reduced 5.96%
172,702 $5.17 Million
Q4 2023

Feb 13, 2024

SELL
$27.94 - $35.44 $271,241 - $344,051
-9,708 Reduced 5.02%
183,653 $5.85 Million
Q3 2023

Nov 07, 2023

BUY
$35.27 - $42.24 $111,135 - $133,098
3,151 Added 1.66%
193,361 $6.82 Million
Q2 2023

Aug 02, 2023

BUY
$37.4 - $42.94 $2.98 Million - $3.43 Million
79,783 Added 72.25%
190,210 $7.23 Million
Q1 2023

May 10, 2023

BUY
$34.88 - $43.22 $15,870 - $19,665
455 Added 0.41%
110,427 $4.17 Million
Q4 2022

Feb 06, 2023

SELL
$33.8 - $47.06 $870,451 - $1.21 Million
-25,753 Reduced 18.97%
109,972 $4.66 Million
Q3 2022

Nov 14, 2022

SELL
$31.52 - $373.61 $137,395 - $1.63 Million
-4,359 Reduced 3.11%
135,725 $4.36 Million
Q2 2022

Aug 08, 2022

BUY
$26.83 - $38.57 $86,607 - $124,503
3,228 Added 2.36%
140,084 $4.55 Million
Q1 2022

May 12, 2022

SELL
$30.95 - $39.68 $783,035 - $1 Million
-25,300 Reduced 15.6%
136,856 $4.95 Million
Q4 2021

Feb 02, 2022

SELL
$35.87 - $47.12 $239,719 - $314,902
-6,683 Reduced 3.96%
162,156 $6.42 Million
Q3 2021

Nov 12, 2021

SELL
$41.55 - $48.72 $629,150 - $737,718
-15,142 Reduced 8.23%
168,839 $7.38 Million
Q2 2021

Aug 03, 2021

BUY
$32.88 - $44.57 $230,160 - $311,990
7,000 Added 3.96%
183,981 $7.51 Million
Q1 2021

May 17, 2021

BUY
$30.92 - $44.4 $398,960 - $572,893
12,903 Added 7.86%
176,981 $5.81 Million
Q4 2020

Feb 11, 2021

BUY
$33.66 - $40.76 $177,859 - $215,375
5,284 Added 3.33%
164,078 $6.67 Million
Q3 2020

Nov 13, 2020

SELL
$33.07 - $38.68 $1.01 Million - $1.19 Million
-30,653 Reduced 16.18%
158,794 $5.81 Million
Q2 2020

Aug 11, 2020

SELL
$20.05 - $33.89 $1.11 Million - $1.87 Million
-55,225 Reduced 22.57%
189,447 $6.42 Million
Q1 2020

May 08, 2020

BUY
$17.15 - $25.22 $141,161 - $207,585
8,231 Added 3.48%
244,672 $5.18 Million
Q4 2019

Feb 07, 2020

BUY
$18.88 - $24.14 $2,605 - $3,331
138 Added 0.06%
236,441 $5.28 Million
Q3 2019

Oct 31, 2019

BUY
$18.0 - $21.38 $4.25 Million - $5.05 Million
236,303 New
236,303 $4.79 Million

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.6B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Oppenheimer Asset Management Inc. Portfolio

Follow Oppenheimer Asset Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.